share_log

施贵宝的期权狂潮:你需要知道的事情

Benzinga ·  Aug 21 15:46

Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BMY usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Bristol-Myers Squibb. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 22% bearish. Among these notable options, 4 are puts, totaling $138,637, and 5 are calls, amounting to $207,540.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $41.0 and $55.0 for Bristol-Myers Squibb, spanning the last three months.

Analyzing Volume & Open Interest

In today's trading context, the average open interest for options of Bristol-Myers Squibb stands at 3613.11, with a total volume reaching 1,952.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bristol-Myers Squibb, situated within the strike price corridor from $41.0 to $55.0, throughout the last 30 days.

Bristol-Myers Squibb 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

SymbolPUT/CALLTrade TypeSentimentExp. DateAskBidPriceStrike PriceTotal Trade PriceOpen InterestVolume
BMYCALLSWEEPBULLISH01/17/25$5.6$5.5$5.6$45.00$56.5K7.7K104
BMYCALLTRADEBULLISH01/16/26$9.25$9.2$9.25$43.00$46.2K6.8K60
BMYCALLSWEEPBULLISH03/21/25$9.25$9.1$9.2$41.00$45.9K151
BMYPUTTRADENEUTRAL01/16/26$7.75$7.65$7.7$52.50$38.5K68950
BMYPUTSWEEPBEARISH01/17/25$1.75$1.69$1.72$45.00$38.0K7.7K265

About Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

After a thorough review of the options trading surrounding Bristol-Myers Squibb, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Current Position of Bristol-Myers Squibb

  • With a trading volume of 4,688,294, the price of BMY is down by -1.48%, reaching $48.26.
  • Current RSI values indicate that the stock is may be approaching overbought.
  • Next earnings report is scheduled for 64 days from now.

What The Experts Say On Bristol-Myers Squibb

3 market experts have recently issued ratings for this stock, with a consensus target price of $46.333333333333336.

  • Consistent in their evaluation, an analyst from TD Cowen keeps a Hold rating on Bristol-Myers Squibb with a target price of $53.
  • An analyst from Deutsche Bank persists with their Hold rating on Bristol-Myers Squibb, maintaining a target price of $45.
  • An analyst from Barclays downgraded its action to Underweight with a price target of $41.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from Benzinga Pro.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment